Active amyloid beta immunization ameliorates synapse loss and phosphorylated-tau accumulation around remaining plaques for up to 14 years after treatment
This study demonstrates that active amyloid-beta immunization in the AN1792 trial provided lasting benefits up to 14 years post-treatment by significantly reducing synapse loss, phosphorylated tau accumulation, and astrogliosis around both remaining and newly formed amyloid plaques in Alzheimer's disease patients.